

## Lothian University Hospitals NHS Trust Department of Cardiology and Department of Pharmacy, Royal Infirmary of Edinburgh

## Isoprenaline

Indication	Asystole Heart block with slow ventricular escape rhythm					
Recommended Dosage	0.01 microgra response)	am/kg/minute -	- 0.15 microgra	am/kg/minute (	titrating the do	se according to
	Doses are ex	pressed in terr	ms of <b>isoprena</b>	aline hydroch	loride	
Recommended Administration	isoprenaline sulphate 1.125mg is equivalent to isoprenaline hydrochloride 1mg					
Administration	IV infusion					
	<ul> <li>Dilute 10ml (2 ampoules of 5ml) of isoprenaline hydrochloride (2mg) in 500ml sodium chloride 0.9% solution for injection OR</li> <li>Dilute 10ml (2 ampoules of 5ml) of isoprenaline hydrochloride (2mg) in 500ml glucose 5% solution of injection</li> </ul>					
	$\ddot{\cdot}$	isoprenaline h	ydrochloride in	fusion strength	n = 4 micrograr	ns/mL
Rate	0.01 microgram/kg/minute – 0.15 microgram/kg/minute (titrating the dose according to response)					
	Dose can be increased in increments of 0.01 microgram/kg/minute.					
	Example calculation: 60kg patient commencing on 0.01 microgram/kg/ minute Isoprenaline infusion.  0.01 micrograms x 60kg = 0.6 micrograms / minute  0.6 micrograms x 60 minutes = 36 micrograms / hour  4 micrograms/mL → 36micrograms/ 4 = 9 mL/hr					
	Example infusion rates:					
	Weight (kg)	Isoprenaline hydrochloride 4 micrograms/mL Infusion Rate (mL/hr)				
	. 0/	0.01	0.02	0.05	0.1	0.15
		microgram /kg/minute	microgram /kg/minute	microgram /kg/minute	microgram /kg/ minute	microgram /kg/minute
	50	7.5	15.0	37.5	75.0	112.5
	55	8.3	16.5	41.3	82.5	123.8
	60	9.0	18.0	45.0	90.0	135.0
	65	9.8	19.5	48.8	97.5	146.3
	70	10.5	21.0	52.5	105.0	157.5
	75 80	11.3 12.0	22.5 24.0	56.3 60.0	112.5 120.0	168.8 180.0
	85	12.0	25.5	63.8	120.0	191.3
	90	13.5	27.0	67.5	135.0	202.5
	95	14.3	28.5	71.3	142.5	213.8
	100	15.0	30.0	75.0	150.0	225.0

Written by: Sophie Davidson Approved by: H Veitch Updated by: Seona Stalker April 2022 Date written: October 2021

Review Date: October 2023

Stability	Stable for 24 hours at room temperature			
Adverse Effects	Tachycardia, cardiac arrhythmias, palpitations, hypotension, nausea, tremor, headache, sweating, facial flushing. Prolonged use has been associated with swelling of the parotid glands.			
Half life	1 to several minutes (depending on rate of injection)			
Monitor	<ul> <li>Continuous ECG monitoring</li> <li>Oxygen saturation as per CCU practice</li> <li>Intermittent non-invasive BP monitoring         <ul> <li>→ every 15 minutes for first hour after starting infusion</li> <li>→ every 30-60 minutes thereafter</li> <li>→ within 15 minutes of each dose increase</li> </ul> </li> </ul>			
Additional Information	Keep unopened ampoules refrigerated (2 °C – 8 °C) and protected from light.			

## References

- 1. INJECTABLE MEDICINES GUIDE. Isoprenaline sulphate *Intravenous monograph*. [online]. Available from: <a href="https://www.injguide.nhs.uk">www.injguide.nhs.uk</a> [Accessed 17 October 2021].
- 2. MARTINDALE THE COMPLETE DRUG REFERENCE. Isoprenaline Drug monograph. [online]. Available from: <a href="https://www.medicinescomplete.com/">https://www.medicinescomplete.com/</a> [Accessed 11 May 2017]
- 3. Medicines.org.uk. 2021. Isoprenaline Macure 0.2mg/ml concentrate for solution for infusion Summary of Product Characteristics (SmPC) (emc). [online] Available at: <a href="https://www.medicines.org.uk/emc/product/12511">https://www.medicines.org.uk/emc/product/12511</a> [Accessed 17 October 2021].

Written by: Sophie Davidson Approved by: H Veitch Updated by: Seona Stalker April 2022

Date written: October 2021 Review Date: October 2023